<DOC>
	<DOCNO>NCT01019473</DOCNO>
	<brief_summary>This study ass efficacy , safety tolerability AFQ056 add optimize standard therapy patient Huntington 's disease reduce chorea .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability AFQ056 Patients With Huntington 's Disease Reducing Chorea</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Chorea</mesh_term>
	<criteria>Huntington 's disease ( base DNA test polyQ &gt; 36 ) UHDRS maximal chorea score &gt; 10 patient concomitant Huntington 's medication ( antidepressant , neuroleptic , benzodiazepine ) allow total daily dose dose regimen stable least one month prior randomization female patient without childbearing potential ( postmenopausal surgically sterilize ) , patient must use doublebarrier local contraception patient mark cognitive impairment ( MMSE less 18 ) , presence psychosis and/or confusional state patient history presence renal impairment and/or liver disease Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Huntington 's disease</keyword>
	<keyword>Chorea</keyword>
	<keyword>Dyskinesia</keyword>
</DOC>